Immuneering Corporation Increase (Decrease) in Accrued Liabilities
Immuneering Corporation (IMRX) reported Increase (Decrease) in Accrued Liabilities of -$3.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- Immuneering Corporation increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $1.03M, a 10.40% decline year-over-year.
- Immuneering Corporation increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.78M.
- Immuneering Corporation increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $990.50K, a 160.45% increase year-over-year.
- Immuneering Corporation increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $2.37M, a 183.23% increase year-over-year.
- Immuneering Corporation increase (decrease) in accrued liabilities for fiscal 2025 was $2.90M.
- Immuneering Corporation increase (decrease) in accrued liabilities for fiscal 2024 was -$200.83K, a 127.82% decline from fiscal 2023.
- Immuneering Corporation increase (decrease) in accrued liabilities for fiscal 2023 was $721.99K, a 52.14% increase from fiscal 2022.
- Immuneering Corporation increase (decrease) in accrued liabilities for fiscal 2022 was $474.57K, a 85.36% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.75M 10-Q · filed 2026-08-05 | -$2.76M derived: sum of 3 quarters · filed 2026-08-05 | -$390.09K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$4.78M 10-Q · filed 2026-05-15 | -$3.79M derived: sum of 2 quarters · filed 2026-05-15 | -$1.42M derived: sum of 3 quarters · filed 2026-05-15 | -$270.38K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $990.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $3.36M derived: sum of 2 quarters · filed 2026-03-06 | $4.51M derived: sum of 3 quarters · filed 2026-08-05 | $2.90M 10-K · filed 2026-03-06 |
| 2025-09-30 | $2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.52M derived: sum of 2 quarters · filed 2026-08-05 | $1.91M 10-Q · filed 2025-11-12 | $2.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$458.17K 10-Q · filed 2026-08-05 | -$77.87K derived: sum of 3 quarters · filed 2026-08-05 | $757.81K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.61M 10-Q · filed 2026-05-15 | -$1.23M derived: sum of 2 quarters · filed 2026-05-15 | -$392.70K derived: sum of 3 quarters · filed 2026-05-15 | $953.02K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $380.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.22M derived: sum of 2 quarters · filed 2026-03-06 | $2.56M derived: sum of 3 quarters · filed 2026-03-06 | -$200.83K 10-K · filed 2026-03-06 |
| 2024-09-30 | $835.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.18M derived: sum of 2 quarters · filed 2025-11-12 | -$581.13K 10-Q · filed 2025-11-12 | $1.37M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.42M 10-Q · filed 2025-08-13 | $529.39K derived: sum of 3 quarters · filed 2025-08-13 | $1.38M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$2.76M 10-Q · filed 2025-05-05 | -$816.33K derived: sum of 2 quarters · filed 2025-05-05 | $33.55K derived: sum of 3 quarters · filed 2025-05-05 | $52.82K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.80M derived: sum of 2 quarters · filed 2025-03-20 | $2.82M derived: sum of 3 quarters · filed 2025-03-20 | $721.99K 10-K · filed 2025-03-20 |
| 2023-09-30 | $849.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $869.15K derived: sum of 2 quarters · filed 2024-11-13 | -$1.22M 10-Q · filed 2024-11-13 | -$1.14M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $19.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.07M 10-Q · filed 2024-08-06 | -$1.99M derived: sum of 3 quarters · filed 2024-08-06 | $127.94K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$2.09M 10-Q · filed 2024-05-07 | -$2.00M derived: sum of 2 quarters · filed 2024-05-07 | $108.67K derived: sum of 3 quarters · filed 2024-05-07 | $616.55K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $89.03K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.20M derived: sum of 2 quarters · filed 2024-03-01 | $2.71M derived: sum of 3 quarters · filed 2024-03-01 | $474.57K 10-K · filed 2024-03-01 |
| 2022-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.62M derived: sum of 2 quarters · filed 2023-11-09 | $385.54K 10-Q · filed 2023-11-09 | $936.62K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $507.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.73M 10-Q · filed 2023-08-03 | -$1.18M derived: sum of 3 quarters · filed 2023-08-03 | -$1.11M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$2.24M 10-Q · filed 2023-05-04 | -$1.68M derived: sum of 2 quarters · filed 2023-05-04 | -$1.61M derived: sum of 3 quarters · filed 2023-05-04 | $393.72K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $551.08K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $621.06K derived: sum of 2 quarters · filed 2023-03-06 | $2.63M derived: sum of 3 quarters · filed 2023-03-06 | $3.24M 10-K · filed 2023-03-06 |
| 2021-09-30 | $69.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.08M derived: sum of 2 quarters · filed 2022-11-10 | $2.69M 10-Q · filed 2022-11-10 | $2.43M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.62M 10-Q · filed 2022-08-10 | $2.36M derived: sum of 3 quarters · filed 2022-08-10 | $2.68M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $611.87K 10-Q · filed 2022-05-10 | $354.82K derived: sum of 2 quarters · filed 2022-05-10 | $672.58K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$257.05K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $60.71K derived: sum of 2 quarters · filed 2022-03-10 | $488.64K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $317.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $745.69K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $427.93K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |